Lundbeck in global research agreement with UK's Asterand  

2009.07.27
The Danish pharmaceutical company has entered a global research agreement with UK's Asterand plc, which provides human tissue and human tissue-based services
Less than two weeks after Danish pharmaceutical company Lundbeck announced the domestic acquisition of biotech company NeuronIcon, it is back in the news again – this time regarding a global research agreement with the British company Asterand plc, which provides human tissue and human tissue-based services. The news is reported by financial daily newspaper Børsen.

The research agreement gives Lundbeck access to Asterand’s XpressBANK of human tissue and clinical data, as well as the PhaseZERO drug discovery services platform to advance development of treatments for psychiatric and neurological disorders. The financial aspects of the deal have not been revealed.
 
In a press release from Asterand, CEO Martyn Coombs expressed pride and pleasure that Lundbeck had chosen Asterand as a preferred human tissue solutions provider, and commented: "The extended collaboration provides Asterand with the opportunity to assist Lundbeck in its quest to find treatments for difficult to treat diseases such as Alzheimer’s, Parkinson’s and schizophrenia."
 
Link > Lundbeck                   

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×